Amgen Biosimilars in the News | Amgen Biosimilars
CLEAR

Amgen in the News

The latest information about Amgen Biosimilars

News Archive

2019
Dec. 2019 
LinkedIn: Unlocking Biosimilar Potential: Confidence Is Key
 
The Atlantic: FDA Approved Biosimilars Offer More Treatment Options (Amgen sponsored)
Sep. 2019 
Center for Biosimilars: Safety and Scientific Standards First: Why Biosimilars Require Clinical Testing
 
BioWorld: U.S. Biosimilar Market “Thriving” Without Government Intervention
 
S&P Global: Amgen's Rise In Biosimilar Space May Signal Turning Tide For U.S. Market
Aug. 2019 
Pink Sheet: Amgen’s Nonconformist Position On Biosimilar Payment Policy Reflects Market Strategy
Jul. 2019 
Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (rituximab)
 
Amgen And Allergan's MVASI™ (bevacizumab-awwb) And KANJINTI™ (trastuzumab-anns) Now Available In The United States
Jun. 2019 
Biosimilar Development: How Can Biosimilars Make Headway In The U.S. Market?
 
Center for Biosimilars: What’s New in the Biosimilar Labeling, Naming Landscape
 
Oncology Live: Biosimilars in Cancer Care: Potentially Improving Patient Access to Essential Therapies
 
FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)
May 2019 
Center for Biosimilars: What Can US Learn About Biosimilars From Europe?
 
American Journal of Managed Care: Biosimilar Experts Give Highlights of US Uptake Issues
 
Journal of Clinical Pathways: Biosimilar Headway in the US: Regulatory and Manufacturer Perspectives
 
PharmaVOICE: The Biosimilars Market
Apr. 2019 
STAT: U.S. biologics and biosimilars need distinguishable names
 
LinkedIn: Biosimilars are not generics: complexity demands rigorous manufacturing standards
 
Kaiser Health News: U.S. biologics and biosimilars need distinguishable names
 
BioCentury: Gottlieb, Biosimilars Companies and Consultants Reject Price Control Proposal
Mar. 2019 
Pink Sheet: Woodcock: Concerns About US FDA's Biosimilars Suffix Policy Detached From Reality
 
STAT+: What’s in a name? FDA changes course for biosimilar names and upsets generic makers
Jan. 2019 
STAT+: Biosimilars and interchangeability: The FDA’s science-based standards will ensure safety
2018
Dec. 2018 
Morning Consult: A Level Playing Field for Biosimilar Success
Nov. 2018 
STAT: Overcoming Challenges in the US Biosimilars Marketplace (Amgen sponsored)
 
BioWorld: Interchangeability Not in the Driver’s Seat for Biosimilars
Oct. 2018 
Financial Times: Rivals Line Up to Take on World’s Best-Selling Drug
 
Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration
Sept. 2018 
Pink Sheet: Biosimilar Bridging Study Waivers: Public Health Prerogative or Trade Secret ‘Taking’?
 
Scrip: From Interchangeability to Exclusivity: US FDA Looks for Ways to Make Biologics Market More Competitive
 
S&P Global Market Intelligence: Drugmakers, Public Weigh in on Efforts to Boost US Biosimilar Competition
 
Regulatory Focus: Companies Discuss Biosimilars, Suggest Reforms at FDA Public Meeting
Previous: Media Releases Next: Amgen Policy Positions